ClinConnect ClinConnect Logo
Search / Trial NCT01248507

Predictive Questionnaires for Risk of Acute COPD (Chronic Obstructive Pulmonary Disease) Exacerbations

Launched by ASTRAZENECA · Nov 24, 2010

Trial Information

Current as of May 28, 2025

Completed

Keywords

Copd

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Signed informed consent
  • Age ≥ 40 years
  • Patients fulfilling criteria for COPD according to the Global initiative for chronic obstructive pulmonary disease (GOLD) stage I or higher
  • Smokers or ex-smokers of at least 10 pack-years
  • * Patients suffering an AECOPD either:
  • 1. Admitted to hospital due to AECOPD (severe exacerbation) or
  • 2. Confirmed AECOPD at GP (general practitioner) setting (moderate exacerbation) Definition AECOPD: Increase in respiratory symptoms requiring treatment with oral corticosteroids, antibiotics or both.
  • Exclusion Criteria:
  • Patients who have never smoked
  • Patients with active long-term respiratory disease (e.g. bronchial asthma, cystic fibrosis, severe bronchiectasis, malignancy, restrictive lung diseases etc.)
  • Exacerbation of COPD due to other causes such as pneumothorax and acute decompensated congestive heart failure
  • Difficulties in communication (cognitive deterioration, sensorial disability, language barriers)
  • Severe disease with poor vital prognosis (life length expectancy less than one year)

About Astrazeneca

AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

Madrid, , Spain

Patients applied

0 patients applied

Trial Officials

AstraZeneca AstraZeneca

Study Director

AstraZeneca

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials